Jazz Pharmaceuticals plc announced that the US Food and Drug Administration (FDA) approved Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy. Xywav is an oxybate product with 92 percent less sodium than sodium oxybate at the recommended dosage range of 6 to 9 grams.

Read the full announcement on this link.